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ABSTRACTS

percent of patients had high triglycerides (grade 1) and twelve percent

for all seasons (63.7%, p<0.001; 65.5%, p=0.08; 66.8%, p=0.08) but

grade 2. Fifty-two percent had either transaminase affected. None of

higher uptake compared to Georgia (all p<0.001). Leukemia/lymphoma

the patients with abnormal liver function tests required therapeutic

patients had higher influenza vaccination uptake compared to solid

interventions or interruption of therapy.

tumor and brain tumor patients for all three seasons. Among the

Conclusion: As the first step of project, we completed our baseline

inpatient oncology and SCD cohorts, there was no significant change

assessment and will do the following modifications to our monitor-

in vaccination uptake before and after the inpatient intervention

ing plan: if the baseline panel including CBC with differential, CMP

(leukemia/lymphoma p=0.19; solid tumor p=0.42; brain tumor p=0.77;

and lipid profile is normal, we will not re-test chemistries, renal func-

SCD p=0.33). Concurrent chemotherapy and prior influenza vaccina-

tion or bilirubin. Every three months will obtain: CBC with differen-

tion correlated strongly with vaccine uptake for all three oncology

tial, transaminases, cholesterol and triglycerides. We will obtain an offi-

groups (all p<0.01). Prior influenza vaccination was strongly correlated

cial nutritional consult for high cholesterol and/or triglycerides and will

with vaccine uptake in inpatient SCD patients (p<0.001), though his-

consult gastroenterology for two consecutive grade 2 transaminitis.

tory of acute chest syndrome, splenectomy, chronic transfusion, and

We will proceed with this monitoring plan for 1 year and study the data

prior pneumococcal vaccination were not.

at the end of twelve months.

Conclusion: Pediatric oncology and SCD populations have similar
to greater vaccination uptake compared to Georgia. There was no
improvement in influenza vaccine uptake from the inpatient order set,

Poster # 178|||INFLUENZA VACCINATION IN ONCOLOGY

suggesting that future interventions should focus on outpatient.

AND SICKLE CELL DISEASE AFTER AN INPATIENT ADMISSION
ORDER SET
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Background: Influenza causes greater morbidity in pediatric oncology
and sickle cell disease (SCD) patients versus the general pediatric pop-

Background: Favorable survival rates in pediatric oncology allow the

ulation and can lead to delays in cancer-directed therapy. Prior studies

opportunity for patients to return to school, during or after treatment.

have improved vaccine uptake through outpatient interventions, but

This can be a significant challenge, exposing vulnerability to peer rejec-

no studies have looked at inpatient interventions.

tion. Successful school reintegration for childhood cancer patients and

Objectives: Determine influenza vaccination rates of pediatric oncol-

survivors is integral to their academic advancement as well as achieve-

ogy and SCD patients in a low- vaccination state (Georgia, USA) and

ment of normal psychosocial milestones. School reentry assistance is

determine the efficacy of an inpatient opt-out admission order set for

provided at institutions around the United States, but that assistance

improving influenza vaccination.

is significantly varied without any guidelines for standardization.

Design/Method: A retrospective chart review was conducted of all

Objectives: This double-arm descriptive study, aimed to establish a

pediatric oncology and SCD patients treated at Children’s Healthcare

framework from which to optimize a school reintegration intervention

of Atlanta (CHOA) during the last three influenza seasons (Septem-

for both patients and their classroom peers.

ber 1–April 30; 2017-2018, 2018-2019, 2019-2020). For each season,

Design/Method: This study utilized age appropriate surveys to evalu-

eligible oncology patients were receiving or within 6 months of com-

ate the knowledge and concerns of 3rd-8th grade students in Michigan

pletion of cancer therapy at the start of each season, while eligible

regarding friends with cancer. The study also utilized age appropriate

SCD patients were admitted at least once annually. A system-wide opt-

surveys to evaluate input from patients at a Michigan academic pedi-

out inpatient admission order set was implemented prior to the 2019-

atric oncology practice regarding return to school during or after can-

2020 influenza season. Vaccination status of patients that were admit-

cer treatment.

ted during an influenza season was collected and compared pre- and

Results: The majority of 3rd-8th grade students correctly answered

post-intervention.

questions related to etiology, prognosis, side effects, and treatment

Results: Approximately 2100 oncology and 750 SCD patients were

of cancer. Respondents in 3rd-5th grade were significantly more likely

eligible per influenza season. US general population influenza rates

than 6th-8th graders to endorse that cancer is contagious (P = 0.0036).

for 2017-2018, 2018-2019, 2019-2020 were 57.9%, 62.6%, 63.8%

Fewer students who had a friend with cancer were worried that their

respectively; Georgia rates were 51.3%, 55.5%, 55.6% respectively.

friend might die, compared to those who did not have a friend with can-

Oncology patients had lower vaccination uptake than the US popula-

cer [3rd-5th graders (P = 0.0002) and 6th-8th graders (P = < 0.0001)].

tion for all three seasons (49.3%, 56.5%, 58.4%, all p<0.001) but sim-

A common theme from patients was a desire to be given extra time for

ilar vaccination uptake to Georgia, except for 2019-2020 (p=0.01).

some assignments, though discreetly such that they do not feel singled

SCD patients had similar to higher uptake compared to the nation

out from their peers.
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Conclusion: This study suggests that peer intervention should focus

than health care providers that are living without the disease. In con-

less on facts about cancer and more on positive childhood cancer

clusion, a peer patient advocate can guide patient education mate-

outcomes, as well as how to be supportive of a peer with cancer who is

rial development and can ensure that the content is more pertinent

returning to school. Additionally, personalized interventions and assis-

and useable for adolescents and young adults with sickle cell disease.

tance for patients should strive to reduce stigma and differentiation

Including a peer patient advocate to develop patient education devel-

from other students. Programs that do not already offer academic

opment for other chronic diseases may be valuable for AEAs with other

assistance, support groups, and peer education should consider adding

chronic health conditions.

these elements for successful return to school.

MacLellan, Harm Reduction, 2017
Sobota, Pediatr Hem/Oncol, 2014
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OF EDUCATIONAL MATERIAL FOR ADOLOSCENT SICKLE
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Background: Sickle cell disease, caused by a genetic mutation in the

Behzad Kharabi Masouleh, MD, Daniel Lee

hemoglobin, leads to chronic anemia, vaso-occlusive pain episodes,

Children’s Hospital Los Angeles, USC Norris Comprehensive Cancer Cen-

multisystem organ damage, and a shortened lifespan. Adolescent and

ter, Keck School of Medicine, Univ of Southern CA, Los Angeles, California,

emerging adult (AEA) sickle cell patients consistently report feeling

United States

alone without support and also lack disease-specific knowledge (Sobota et al., 2014). Peer patient advocates (PPAs) have the same chronic

Background: We present long-term Phase 1 results of ZUMA-4, a

illness as the patients and have become a developing resource in

study of KTE-X19 autologous anti-CD19 CAR T-cell therapy in pedi-

the healthcare system. Traditionally, PPAs assist patients to navigate

atric/adolescent patients with relapsed/refractory B-cell acute lym-

through various medical and life events (MacLellan, 2017).

phoblastic leukemia (R/R B-ALL).

Objectives: The development of educational material by a peer patient

Objectives: Evaluate long-term safety and efficacy of KTE-X19 in pedi-

advocate.

atric/adolescent R/R B-ALL.

Design/Method: The PPA developed a booklet with 10 educational

Design/Method: Patients (aged 2-21 years) with R/R B-ALL (Philadel-

modules based on health information gathered from Got Transition,

phia chromosome-positive allowed) and >5% bone marrow blasts

National Institutes of Health, and American Society of Hematology.

received 2×106 or 1×106 CAR T cells/kg following conditioning

The educational material was used by twelve patients ranging in age

chemotherapy. The primary endpoint was incidence of dose-limiting

from 14-21in a group healthcare program. To assess the value of the

toxicities (DLTs). KTE-X19–formulation was optimized in a second

educational material, each participant was called 1-7 days prior to the

1×106 -dose group using a lower infusion volume (40-mL vs 68-mL).

next group meeting to inquire about what they retained from the pre-

Results: As of 9/9/2020, median follow-up was 36.1 months (range,

vious meeting and their experience with and use of the educational

24.0-53.9), with 24 patients (median age, 14 years [range, 3-20]) of

material. Each interview was then audio-recorded and transcribed into

31 enrolled receiving KTE-X19. Median time from leukapheresis to

a text file that could be used for feedback analysis.

KTE-X19 product release was 14 days. Four patients received 2×106

Results: The participants described the booklet as useful, easy to

cells/kg, with no DLTs in evaluable patients (n=3). Additionally, the

understand, and beneficial to their learning. Having a peer patient

1×106 cells/kg dose level was explored (68-mL, n=11; 40-mL, n=9).

advocate as part of the team that creates the education material

Overall, Grade ≥3 adverse events occurred in 100% of patients, most

can increase pertinent, useable, and relatable information for sickle

commonly hypotension (50%) and anemia (42%). Rates of Grade ≥3

cell adolescent patients. The team learned that while the participants

neurologic events/cytokine release syndrome were 25%/75% (2×106 ),

enjoyed the booklet, the size of the booklet needed to be adjusted

27%/27% (1×106 [68-mL]), and 11%/22% (1×106 [40-mL]). All 4 Grade

to accommodate ease of transport between sessions. The team also

5 events (B-ALL, n=2; disseminated mucormycosis, n=1; Escherichia

implemented a procedure to ask participants about knowledge reten-

sepsis, n=1) were considered unrelated to KTE-X19. Overall complete

tion in between session and incorporated a literacy tool to ensure that

remission (CR) rates (CR + CR with incomplete hematologic recovery)

the material was age appropriate and user friendly for the participants.

were 75%, 64%, and 67% in the 2×106 , 1×106 (68-mL), and 1×106

Conclusion: A peer advocate, through their own personal patient expe-

(40-mL) groups, respectively. Of responding patients, 100% had unde-

rience and basic medical knowledge, can streamline information to

tectable minimal residual disease (MRD). Sixteen patients (2×106 , n=2;

patients. The PPA is more familiar with living with a chronic disease

1×106 [68-mL], n=8; 1×106 [40-mL], n=6) underwent subsequent

